Literature DB >> 14991160

[Cardiovascular prevention and rehabilitation].

C von Schacky1.   

Abstract

The distinction between primary and secondary prevention has been abandoned in favor of cardiovascular prevention, mandating individual risk assessment. First, the individual cardiovascular risk of a person is determined by index diseases like myocardial infarction, peripheral arterial disease or other, or, if absent, by a score consisting of a number of conventional risk factors. According to current guidelines, cardiovascular prevention is indicated, as soon as the risk for fatal cardiovascular disease is > or = 5 %, equivalent to a risk for a major cardiovascular event of > or = 20 %. Non-pharmaceutical approaches are: refraining from smoking, mediterranean diet with fatty fish, physical activity and normal body weight. Blood pressure and diabetes mellitus are optimized. In addition, the following agents are used: platelet inhibitors, beta-blockers, ACE-inhibitors, statins and omega-3 fatty acids. A number of structural problems add to individual factors impeding optimal implementation of cardiovascular prevention in Germany.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14991160     DOI: 10.1007/s00108-003-1119-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  36 in total

Review 1.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors:  Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

2.  Dietary protein and weight reduction: a statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association.

Authors:  S T St Jeor; B V Howard; T E Prewitt; V Bovee; T Bazzarre; R H Eckel
Journal:  Circulation       Date:  2001-10-09       Impact factor: 29.690

3.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.

Authors: 
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

Review 4.  [Nutrition and body weight].

Authors:  H Gohlke
Journal:  Z Kardiol       Date:  2002

5.  Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.

Authors:  Roberto Marchioli; Federica Barzi; Elena Bomba; Carmine Chieffo; Domenico Di Gregorio; Rocco Di Mascio; Maria Grazia Franzosi; Enrico Geraci; Giacomo Levantesi; Aldo Pietro Maggioni; Loredana Mantini; Rosa Maria Marfisi; G Mastrogiuseppe; Nicola Mininni; Gian Luigi Nicolosi; Massimo Santini; Carlo Schweiger; Luigi Tavazzi; Gianni Tognoni; Corrado Tucci; Franco Valagussa
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  Lack of benefit of dietary advice to men with angina: results of a controlled trial.

Authors:  M L Burr; P A L Ashfield-Watt; F D J Dunstan; A M Fehily; P Breay; T Ashton; P C Zotos; N A A Haboubi; P C Elwood
Journal:  Eur J Clin Nutr       Date:  2003-02       Impact factor: 4.016

8.  Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease).

Authors:  R O Bonow; B Carabello; A C de Leon; L H Edmunds; B J Fedderly; M D Freed; W H Gaasch; C R McKay; R A Nishimura; P T O'Gara; R A O'Rourke; S H Rahimtoola; J L Ritchie; M D Cheitlin; K A Eagle; T J Gardner; A Garson; R J Gibbons; R O Russell; T J Ryan; S C Smith
Journal:  Circulation       Date:  1998-11-03       Impact factor: 29.690

9.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

10.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.